Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

🧠 Featured Campaign Deep Dive: Ravel Health

Virtual Care for Chronic Illness in a Fractured System

A growing population of patients with complex chronic illnesses faces years of fragmented care, delayed diagnoses, long specialist wait times, and rising out-of-pocket expenses. Ravel Health was founded by individuals who’ve lived this experience firsthand. Their response: a digital-first, subscription-based healthcare platform designed to support patients managing conditions like Lyme disease, mold toxicity, and Long COVID.

The company is now raising capital through a Regulation Crowdfunding (Reg CF) campaign. With a clinical team in place and patients in 46 states, Ravel is pursuing a scalable model for virtual chronic care. Let’s explore what they’re building—and why it matters.

📍 The Care Gap Ravel Targets

According to the CDC, more than 476,000 Americans are diagnosed with Lyme disease each year, exceeding the number of new breast cancer diagnoses. Many experience ongoing symptoms, often complicated by mold exposure or post-viral fatigue.

But the U.S. healthcare system struggles to support these patients:

• Appointments can take months to secure

• Functional testing is often denied by insurance

• General practitioners may overlook or misdiagnose symptoms

Ravel Health was built to change this. Its co-founders, Kevin Williams and Jaime Intile, designed the platform to reduce friction, create continuity, and integrate clinical disciplines.

🩺 How the Platform Works

Ravel Health functions as a membership-based telehealth clinic tailored to patients with long-term, complex illnesses. Its model blends conventional, functional, and integrative care, delivered by licensed MDs, NPs, and NDs.

Key features include:

• Virtual visits ranging from 30 to 90 minutes

• Personalized treatment protocols

• Direct-to-home labs, test kits, and prescriptions

• Transparent pricing and flexible subscription options

• Discounts through supplier partnerships

• Optional services like provider switching or secure messaging

Initial consultations cost $395, while monthly care plans range from $65 to $305, depending on the frequency and duration of visits.

💼 Traction and Early Signals

Between October 2023 and March 2024, Ravel conducted a six-month pilot in Colorado, testing clinical workflows with 30 patients and seven providers. Based on post-pilot surveys:

• 94% found the platform “very” or “extremely” convenient

• 93% would recommend Ravel to a friend

• 88% rated the experience “very good” or “excellent”

• 81% said Ravel met or exceeded expectations

Following this, Ravel began accepting patients in 9 additional states—and by mid-2024 had expanded to 46 states, with a waitlist of over 500 patients.

The company currently earns approximately $10,000/month in recurring subscription revenue, with five active providers and plans to expand staffing as demand grows.

📊 Revenue Model Breakdown

Ravel earns revenue through three primary streams:

1. Subscription & Visit Fees
   Patients pay per visit or monthly. Ravel retains 30–50% of the cost of each visit.

2. Supplement & Lab Margins
   A 15% markup applies to partner-supplied supplements. Lab interpretations cost $30.

3. Platform Services
   These include $45 messaging charges, $95 provider switches, and reactivation fees.

Patients typically spend $150–$400/month, positioning Ravel competitively against out-of-network care with added coordination and access.

🧭 Who’s Backing Ravel?

Three institutional investors support Ravel Health:

• Peninsula Capital Management

• Right Side Capital

• Jumpstart Foundry

Scott Bedford of Peninsula Capital made a $250K public investment, citing Ravel’s unique value in scalable, personalized care.

Advisors include:

• Dr. Monica Embers, Lyme disease researcher at Tulane

• Dr. Darin Ingels, global Lyme authority

• Dr. Bill Rawls, author and Chief Medical Officer

• Dr. Cathryn Harbor, MD, with decades of functional medicine experience

🛠 Product Roadmap

Ravel’s development plan includes both clinical and platform milestones:

2024

• Expand to 50 states

• Scale the provider network

• Launch national marketing

• Upgrade internal care tools

2025+

• Explore employer health partnerships

• Add AI-powered matching and supplement tracking

• Integrate wearable health data

🧬 Meet the Founders

• Kevin Williams, Co-Founder
  A digital product veteran who redirected his technical skills toward healthcare after his own chronic Lyme experience.

• Jaime Intile, Co-Founder
  A marketing and ops leader whose lived experience inspired her to design more compassionate, integrated systems.

• Dr. Bill Rawls, Chief Medical Officer
  A former OB/GYN who has become a leading voice in holistic Lyme disease protocols following his health transformation.

🌐 Why This Matters

Ravel Health isn’t competing in a crowded virtual urgent care market. It’s creating new infrastructure for a category of patients the system rarely serves well.

This campaign reflects larger shifts toward:

• Patient-driven virtual care

• Transparent pricing models

• Specialized digital clinics

• Holistic approaches to chronic illness

📎 Learn More

Want to explore Ravel’s campaign and see the official offering materials?

👉 Visit the official Reg CF offering page here

📣 Final Take

Ravel Health is building care infrastructure where little existed before. Their clinical model is designed for complexity. Their platform is built around continuity. And their mission is guided by experience, not assumption.

For investors interested in the future of telehealth—and the patients who are often left behind—Ravel invites a deeper exploration.

📌 Required Disclaimers

Become a paying subscriber to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

The Signals. The Stories. The Startup Intel You Won’t Find Elsewhere.:

• • 1 just-launched Reg CF, Reg A, or Reg D campaign
• • 1 closing-soon raise — with momentum, context, and caveats
• • Clear breakdowns, red flags, standout metrics
• • No hype. Just the info serious investors want